



THOMSON REUTERS RESEARCH

A Select List of Published Work by Thomson Reuters Researchers

Since 1988, researchers at Thomson Reuters have conducted studies of disease progression, treatment patterns, health outcomes, and their associated costs to patients, employers, health plans, and the government. These studies have resulted in over 400 peer-reviewed articles published in leading journals, which have made a substantial contribution to the body of literature used to formulate policy decisions and improve healthcare for Americans.

Authors in bold typeface are (or were at the time the work was written) Thomson Reuters staff.

2009

Amin AN, **Lin J**, **Lenhart G**, **Schulman KL**. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. *Thrombosis and Haemostasis* 2009; 102(2): 321–6.*

Bowen JD, **Goetzel RZ**, **Lenhart G**, **Ozminkowski RJ**, Babamoto KS, Portale JD. Using a personal health care cost calculator to estimate future expenditures based on individual health risks. *Journal of Occupational and Environmental Medicine* 2009; 51(4): 449–55.

Carls G, Li T, Panopalis P, **Wang S**, Mell AG, **Gibson TB**, **Goetzel RZ**. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. *Journal of Occupational and Environmental Medicine* 2009; 51(1): 66–79.

Chu E, **Schulman KL**, Zelt S, **Song X**. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. *Cancer* 2009; 115(7): 1412–23.

Chu E, **Shi N**, Wei W, Bendell JC, Cartwright T. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. *Oncology* 2009; 77(3–4): 244–53.*

Citrome L, Reist C, **Palmer L**, **Montejano L**, **Lenhart G**, Cuffel B, Harnett J, Sanders KN. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. *Schizophrenia Research* 2009; 108(1–3): 238–44.*



- Coffey RM, Levit KR, Kassed CA, McLellan AT, Chalk M, Brady TM, Vandivort-Warren R.** Evidence for substance abuse services and policy research: A systematic review of national databases. *Evaluation Review* 2009; 33(2): 103–37.
- Curkendall SM, Natoli JL, Alexander CM, Nathanson BH, Haidar T, Dubois RW.** Inpatient diabetic hypoglycemia: Economic and clinical impact. *Endocrine Practice* 2009; May 6; [Epub ahead of print].*
- Gibson TB, Lee TA, Vogeli CS, Hidalgo J, Carls GS, Sredl K, DesHarnais S, Marder WD, Weiss KB, Williams TV, Shields AE.** A four-system comparison of patients with chronic illness: The Military Health System, Veterans Health Administration, Medicaid, and commercial plans. *Military Medicine* 2009; 174(9): 936–43.*
- Goetzel RZ.** Do prevention or treatment services save money? The wrong debate. *Health Affairs* 2009; 28(1): 37–41.
- Goetzel RZ, Baker KM, Short ME, Pei X, Ozminkowski RJ, Wang S, Bowen JD, Roemer EC, Craun BA, Tully KJ, Baase CM, Dejoy DM, Wilson MG.** First-year results of an obesity prevention program at the Dow Chemical Company. *Journal of Occupational and Environmental Medicine* 2009; 51(2): 125–138.
- Goetzel RZ, Carls GS, Wang S, Kelly E, Mauceri E, Columbus D, Cavuoti A.** The relationship between modifiable health risk factors and medical expenditures, absenteeism, short-term disability, and presenteeism among employees at Novartis. *Journal of Occupational and Environmental Medicine* 2009; 51(4): 487–99.
- Goetzel RZ, Liss-Levinson RC, Goodman N, Kennedy JX.** Development of a community-wide cardiovascular risk reduction assessment tool for small rural employers in upstate New York. *Preventing Chronic Disease* 2009; 6(2): A65.*
- Goetzel RZ, Roemer EC, Short ME, Pei X, Tabrizi MJ, Liss-Levinson RC, Samoly DK, Luisi D, Quitoni K, Dumanovsky T, Silver LD, Ozminkowski RJ.** Health improvement from a worksite health promotion private-public partnership. *Journal of Occupational and Environmental Medicine* 2009; 51(3): 296–304.
- Henke RM, Zaslavsky AM, McGuire TG, Ayanian JZ, Rubenstein LV.** Clinical inertia in depression treatment. *Medical Care* 2009; 47(9): 959–67.
- Lee DW, **Gibson TB, Carls GS, Ozminkowski RJ, Wang S, Stewart EA.** Uterine fibroid treatment patterns in a population of insured women. *Fertility and Sterility* 2009; 91(2): 566–74.*
- Lee DW, Stang PE, Goldberg GA, **Haberman M.** Resource use and cost of diagnostic workup of women with suspected breast cancer. *The Breast Journal* 2009; 15(1): 85–92.
- Li T, **Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ.** Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: A five-year analysis of a large medicaid population. *Arthritis and Rheumatism* 2009; 61(6): 755–763.
- Madeb R, Golijanin D, Noyes K, Fisher S, **Stephenson JJ, Long SR, Knopf J, Lyman GH, Messing EM.** Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. *Cancer* 2009; 115(12): 2660–70.



- Madjid M, **Curkendall S**, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. *Cardiology* 2009; 113(2): 98–107.*
- Mark TL, Gibson TB**, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. *American Journal of Managed Care* 2009; 15(2): 123–31.
- Mark TL, Kassed CA**, Vandivort-Warren R, **Levit KR**, Kranzler HR. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. *Drug and Alcohol Dependence* 2009; 99(1–3): 345–9.*
- Mark TL, Levit KR**, Buck JA. Datapoints: Psychotropic drug prescriptions by medical specialty. *Psychiatric Services* 2009; 60(9): 1167.
- Piedra PA, **Schulman KL**, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. *Pediatrics* 2009; 124(1): 170–8.
- Rothbard AB, **Miller K**, Lee S, Blank M. Revised cost estimates of Medicaid recipients with serious mental illness and HIV-AIDS. *Psychiatric Services* 2009; 60(7): 974–7.
- Russell M, **Chu BC**, Banerjee A, Fan AZ, Trevisan M, Dorn JM, Gruenewald P. Drinking patterns and myocardial infarction: A linear dose-response model. *Alcoholism, Clinical and Experimental Research* 2009; 33(2): 324–31.*
- Saif MW, **Shi N**, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. *World Journal of Gastroenterology* 2009; 15(35): 4415–22.
- Shi N**, Foley K, **Lenhart G**, Badamgarav E. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. *Bone* 2009; August 5; [Epub ahead of print].
- Short ME, Goetzel RZ, Pei X, Tabrizi MJ, Ozminkowski RJ, Gibson TB**, Dejoy DM, Wilson MG. How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. *Journal of Occupational and Environmental Medication* 2009; 51(7): 786–96.
- Silverman S, Dukes EM, **Johnston SS**, Brandenburg NA, Sadosky A, **Huse DM**. The economic burden of fibromyalgia: Comparative analysis with rheumatoid arthritis. *Current Medical Research and Opinion* 2009; 25(4): 829–40.*
- Song X, Long SR, Marder WD**, Sullivan SD, Kallich J. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. *Annals of Pharmacotherapy* 2009; 43(7): 1203–10.
- Unruh L, **Russo CA**, Jiang HJ, Stocks C. Can state-level data be used to develop a national, standardized dataset of hospital nurse staffing measures? *Western Journal of Nursing Research* 2009; 31(1): 66–88.
- White RR, **Lenhart G**, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. *Pharmacoeconomics* 2009; 27(9): 781–92.



Wish J, **Schulman K**, Law A, Nassar G. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: A retrospective claims database analysis. *Kidney and Blood Pressure Research* 2009; 32(2): 110–118.

2008

Alegría M, Chatterji P, Wells K, **Cao Z**, Chen CN, Takeuchi D, Jackson J, Meng XL. Disparity in depression treatment among racial and ethnic minority populations in the United States. *Psychiatric Services* 2008; 59(11): 1264–72.*

Baker KM, **Goetzel RZ**, **Pei X**, Weiss AJ, **Bowen J**, **Tabrizi MJ**, Nelson CF, Metz RD, Pelletier KR, Thompson E. Using a return-on-investment estimation model to evaluate outcomes from an obesity management worksite health promotion program. *Journal of Occupational and Environmental Medicine* 2008; 50(9): 981–990.

Baser O, **Palmer L**, **Stephenson J**. The estimation power of alternative comorbidity indices. *Value in Health* 2008; May 16; [Epub ahead of print].

Bray J, Vandivort R, Dilonardo J, Dunlap L, **Schroeder D**, **Forhan C**, **Miller K**. Healthcare utilization of individuals with opiate use disorders: An analysis of integrated Medicaid and state mental health/substance abuse agency data. *Journal of Behavioral Health Services & Research* 2008; 35(1): 91–106.

Carls GS, Lee DW, **Ozminkowski RJ**, **Wang S**, **Gibson TB**, Stewart E. What are the total costs of surgical treatment for uterine fibroids? *Journal of Women's Health* 2008; 17(7): 1119–32.

Chernew M, **Gibson TB**. Cost sharing and HEDIS performance. *Medical Care Research and Review* 2008; 65(6): 713–28.

Chernew M, **Gibson TB**, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. *Journal of General Internal Medicine* 2008; 23(8): 1131–6.

Coffey RM, Buck JA, **Kassed CA**, Dilonardo J, **Forhan C**, **Marder WD**, Vandivort-Warren R. Transforming mental health and substance abuse data systems in the United States. *Psychiatric Services* 2008; 59(11): 1257–63.

Curkendall SM, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois, RW. Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter? *Arthritis and Rheumatism* 2008; 59(10): 1519-26.*

Della LJ, DeJoy DM, **Goetzel RZ**, **Ozminkowski RJ**, Wilson MG. Assessing management support for worksite health promotion: psychometric analysis of the leading by example (LBE) instrument. *American Journal of Health Promotion* 2008; 22(5): 359–67.



- DeJoy DM, Wilson MG, **Goetzel RZ**, **Ozminkowski RJ**, **Wang S**, **Baker KM**, Bowen HM, Tully KJ. Development of the Environmental Assessment Tool (EAT) to measure organizational physical and social support for worksite obesity prevention programs. *Journal of Occupational and Environmental Medicine* 2008; 50(2): 126–137.
- Dilonardo J, **Coffey R**, Vandivort-Warren R, Buck J. Inpatient utilization for persons with co-occurring disorders. *Psychiatric Services* 2008; 59(1): 14.
- Durden ED**, **Huse D**, Ben-Joseph R, **Chu BC**. Economic costs of obesity to self-insured employers. *Journal of Occupational and Environmental Medicine* 2008; 50(9): 991–7.
- Dworkin RH, White R, O'Connor AB, **Hawkins K**. Health care expenditure burden of persisting herpes zoster pain. *Pain Medicine* 2008; 9(3): 348–53.
- Foster SA, **Foley KA**, Meadows ES, Johnston JA, **Wang S**, Pohl GM, **Long SR**. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. *BMC Women's Health* 2008; 8(1): 24.*
- Foster SA, **Foley KA**, Meadows ES, Johnston JA, **Wang S**, Pohl GM, **Long SR**. Characteristics of patients initiating teriparatide for the treatment of osteoporosis. *Osteoporosis International* 2008; 19(3): 373–7.*
- Gibson TB**, Ng E, **Ozminkowski RJ**, **Wang S**, Burton WN, **Goetzel RZ**, Maclean R. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. *Journal of Occupational and Environmental Medicine* 2008; 50(11): 1261–1272.
- Glazer J, McGuire TG, **Cao Z**, Zaslavsky A. Using global rating of health plans to improve the quality of health care. *Journal of Health Economics* 2008; 27(5): 1182–95.
- Goetzel RZ**, Luisi D, **Ozminkowski RJ**, Roemer EC, Taher S. Baseline characteristics of workers at ten New York City employers recruited for a private-public research collaborative. *Journal of Occupational and Environmental Medicine* 2008; 50(2): 190–201.
- Goetzel RZ**, **Ozminkowski RJ**. The health and cost benefits of work site health-promotion programs. *Annual Review of Public Health* 2008; 29: 303–23.
- Goetzel RZ**, **Ozminkowski RJ**, **Bowen J**, **Tabrizi MJ**, Weiss A, Hohlbauch A, DeJoy DM, Wilson M, Roemer EC, Mummert A, **Baker K**, **Short M**, Liss-Levinson R, Samoly D. Employer integration of health promotion and health protection programs. *International Journal of Workplace Health Management* 2008; 1(2): 109–122.
- Hawkins K**, **Wang S**, Rupnow M. Direct cost burden among insured US employees with migraine. *Headache* 2008; 48(4): 553–63.
- Henke RM**, Chou AF, Chanin JC, Zides AB, Scholle SH. Physician attitude toward depression care interventions: Implications for implementation of quality improvement initiatives. *Implementation Science* 2008; 3(1): 40.
- Hochberg MC, **Johnston SS**, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. *Current Medical Research and Opinion* 2008; 24(2): 469–80.*



- Houchens RL**, Elixhauser A, Romano P. How often are potential “patient safety events” present on admission? *Joint Commission Journal on Quality and Patient Safety* 2008; 34(3): 154–163.*
- Johnston SS, Mark TL**, Dirani R. Smoking cessation: The value of a comprehensive carved-in benefit. *American Journal of Health Promotion* 2008; 23(2): 85–7, ii.
- Kranzler HR, **Stephenson JJ, Montejano L, Wang S**, Gastfriend DR. Persistence with oral naltrexone for alcohol treatment: Implications for health-care utilization. *Addiction* 2008; 103(11): 1801–8.*
- Levit KR, Kassed CA, Coffey RM, Mark TL**, Stranges EM, Buck JA, Vandivort-Warren R. Future funding for mental health and substance abuse: Increasing burdens for the public sector. *Health Affairs* 2008; 27(6): w513–22.
- Mark TL**. Receipt of psychotherapy by adolescents taking antidepressants. *Psychiatric Services* 2008; 59(9): 963.*
- Mark TL**, Fortner B, Johnson G. Evaluation of a tablet PC technology to screen and educate oncology patients. *Supportive Care in Cancer* 2008; 16(4): 371–8.
- Mark TL**, Johnson G, Fortner B, **Ryan K**. The benefits and challenges of using computer-assisted symptom assessments in oncology clinics: Results of a qualitative assessment. *Technology in Cancer Research & Treatment* 2008; 7(5): 401–6.
- Mark TL**, Harwood HJ, McKusick DC, King EC, Vandivort-Warren R, Buck JA. Mental health and substance abuse spending by age, 2003. *Journal of Behavioral Health Services and Research* 2008; 35(3): 279–89.
- Mitchell SG, Goetzel RZ, Ozminkowski RJ**. The value of worksite health promotion. *ACSM’s Health & Fitness Journal* 2008; 12(2): 23–27.
- Mucha L**, Shaohung S, Cuffel B, McRae T, **Mark TL**, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer’s disease. *Journal of Managed Care Pharmacy* 2008; 14(5): 451–61.
- Naydeck BL, Pearson JA, **Ozminkowski RJ**, Day BT, **Goetzel RZ**. The impact of the Highmark employee wellness programs on 4-year healthcare costs. *Journal of Occupational and Environmental Medicine* 2008; 50(2): 146–156.
- Peters PH, Moscona A, **Schulman KL**, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. *Medscape Journal of Medicine* 2008; 10(6): 131.*
- Romanowicz M, **Stephenson JJ**, Del Rosso JQ, **Lenhart G**. Healthcare utilization and costs of patients with rosacea in an insured population. *Journal of Drugs in Dermatology* 2008; 7(1): 41–9.*
- Sunycz JA, **Mucha L, Baser O**, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. *Osteoporosis International* 2008; 19(10): 1421–9.
- Wish JB, Nassar GM, **Schulman K**, del Aguila M, Provenzano R. Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease. *Clinical Nephrology* 2008; 69(4): 251–9.*



Yazici Y, **Shi N**, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. *Bulletin of the NYU Hospital for Joint Diseases* 2008; 66(2): 77–85.

2007

Barr C, **Schulman K**, Iacuzio D, Bradley J. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. *Current Medical Research and Opinion* 2007; 23(3): 523–31.*

Baser O. Choosing propensity score matching over regression adjustment for causal inference: When, why and how it makes sense. *Journal of Medical Economics* 2007; 10(4): 379–391.

Baser O. Modeling transformed health care cost with unknown heteroskedasticity. *Applied Economic Research* 2007; 01: 1–6.

Baser O. Using propensity score matching techniques for average treatment effect: Application to triptan use. In *Proceedings of the International Conference on Health Policy Research*, October 28-30 2005, Boston, MA. American Statistical Association; 2007: 4334–4339.

Blumentals WA, **Schulman KL**. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: Results from a retrospective population-based study. *Current Medical Research and Opinion* 2007; 23(12):2961–70.*

Blumentals WA, **Song X**. The safety of oseltamivir in patients with influenza: Analysis of healthcare claims data from six influenza seasons. *Medscape General Medicine* 2007; 9(4): 27–32.

Botteman MF, **Ozminkowski RJ**, **Wang S**, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: A decision analytical model. *CNS Drugs* 2007; 21(4): 319–334.

Brixner DI, **Lenhart G**, Young DC, Samuelson WM. The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. *Current Medical Research and Opinion* 2007; 23(11): 2887–95.*

Chu BC, Millis S, Arango-Lasprilla JC, Hanks R, Novack T, Hart T. Measuring recovery in new learning and memory following traumatic brain injury: A mixed-effects modeling approach. *Journal of Clinical and Experimental Neuropsychology* 2007; 29(6): 617–25.

Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. *HIV Medicine* 2007; 8(8): 483–90.*

Dworkin RH, White R, O'Connor AB, **Baser O**, **Hawkins K**. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. *Journal of the American Geriatrics Society* 2007; 55(8): 1168–75.



- Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, **Young JK**, Cooper LM. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: A database cohort study of hospital mortality, length of stay, and costs. *Current Medical Research and Opinion* 2007; 23(1): 235–44.*
- Foley KA**, Foster SA, Meadows ES, **Baser O**, **Long SR**. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. *Medical Care* 2007; 45(9): 902–6.*
- Fowler JS, Volkow ND, **Kassed CA**, Chang L. Imaging the addicted human brain. *Science and Practice Perspectives* 2007; 3(2): 4–16.
- Gabel JR, Whitmore H, Pickreign JD, **Levit KR**, **Coffey RM**, Vandivort-Warren R. Substance abuse benefits: Still limited after all these years. *Health Affairs* 2007; 26(4): w474–82.
- Goetzel RZ**, **Ozminkowski RJ**, Pelletier KR, Metz RD, Chapman LS. Emerging trends in health and productivity management. *American Journal of Health Promotion* 2007; 22(1): Suppl 1–7, iii.
- Goetzel RZ**, Reynolds K, Breslow L, Roper WL, **Shechter D**, Stapleton DC, Lapin PJ, McGinnis JM. Health promotion in later life: It's never too late. *American Journal of Health Promotion* 2007; 21(4): 1–5, iii.
- Goetzel RZ**, **Shechter D**, **Ozminkowski RJ**, Marmet PF, **Tabrizi MJ**, Roemer EC. Promising practices in employer health and productivity management efforts: Findings from a benchmarking study. *Journal of Occupational and Environmental Medicine* 2007; 49(2): 111–130.
- Goetzel RZ**, **Shechter D**, **Ozminkowski RJ**, Stapleton DC, Lapin PJ, McGinnis JM, Gordon CR, Breslow L. Can health promotion programs save Medicare money? *Clinical Interventions in Aging* 2007; 2(1): 117–122.
- Hawkins K**, **Wang S**, Rupnow MF. Indirect cost burden of migraine in the United States. *Journal of Occupational and Environmental Medicine* 2007; 49(4): 368–374.
- Huse DM**, von Mehren M, **Lenhart G**, Joensuu H, Blanke C, Feng W, Finkelstein S, Demetri G. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. *Clinical Drug Investigation* 2007; 27(2): 85–93.
- Hutchings A, Calloway M, Choy E, Hooper M, Hunter DJ, Jordan JM, Zhang Y, **Baser O**, **Long S**, **Palmer L**. The Longitudinal Examination of Arthritis Pain (LEAP) study: Relationships between weekly fluctuations in patient-rated joint pain and other health outcomes. *The Journal of Rheumatology* 2007; 34(11): 2291–300.*
- Krupski TL, **Foley KA**, **Baser O**, **Long S**, Macarios D, Litwin MS. Health care cost associated with prostate cancer, androgen deprivation therapy, and bone complications. *The Journal of Urology* 2007; 178(4 Pt 1): 1423–8.
- Kutikova L, Bowman L, **Chang S**, **Long SR**, Thornton DE, **Crown WH**. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. *Journal of Neurooncology* 2007; 81(1): 61–5.*
- Larson MJ, **Miller K**, Fleming KJ. Treatment with antidepressant medications in private health plans. *Administration and Policy in Mental Health* 2007; 34(2): 116–26.*



- Larson MJ, **Miller K**, Fleming KJ, Teich JL. Mental health services for children in large, employer-based health plans, 1999. *The Journal of Behavioral Health Services & Research* 2007; 34(1): 56–72.*
- Lee DW, **Ozminkowski RJ**, **Carls GS**, **Wang S**, **Gibson TB**, Stewart EA. The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. *Journal of Occupational and Environmental Medicine* 2007; 49(5): 493–506.*
- Lee TA, Shields AE, Vogeli C, **Gibson TB**, Woong-Sohn M, **Marder WD**, Blumenthal D, Weiss KB. Mortality rate in veterans with multiple chronic conditions. *Journal of General Internal Medicine* 2007; 22 Suppl 3: 403–7.*
- Mark T**, Axelsen K, **Mucha L**, **Sadkova Y**. Racial differences in switching, augmentation and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. *The American Journal of Managed Care* 2007; 13 Suppl 3: S72–9.*
- Mark TL**, **Levit KR**, **Coffey RM**, Buck JA, Vandivort-Warren R. Mental health treatment expenditure trends, 1986–2003. *Psychiatric Services* 2007; 58(8):1041–8.
- Mark TL**, **Levit KR**, Vandivort-Warren R, **Coffey RM**, Buck JA, the SAMHSA Spending Estimates Team. Trends in spending for substance abuse treatment, 1986–2003. *Health Affairs* 2007; 26(4): 1118–28.
- Martin M**, Blaisdell-Gross B, Fortin EW, Maruish ME, Manocchia M, Sun X, Walker DR, Apple JL, Ware JE. Health-related quality of life of heart failure and coronary artery disease patients improved during participation in disease management programs: A longitudinal observational study. *Disease Management* 2007; 10(3): 164–78.
- Mortimer JE, **Schulman K**, Kohles JD. Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease. *Clinical Breast Cancer* 2007; 7(9): 682–9.*
- Nallamotheu BK, **Young J**, Gurm HS, **Pickens G**, **Safavi K**. Recent trends in hospital utilization for acute myocardial infarction and coronary revascularization in the United States. *American Journal of Cardiology* 2007; 99(6): 749–53.*
- Orzeck EA, **Shi N**, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. *Clinical Therapeutics* 2007; 29(10): 2246–55.*
- Ozminkowski RJ**, **Wang S**, **Long SR**. The impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in Medicaid plans. *Disease Management and Health Outcomes* 2007; 15(1): 41–55.
- Ozminkowski RJ**, **Wang S**, Walsh JK. The direct and indirect costs of untreated insomnia in the United States. *Sleep* 2007; 30(3): 263–73.
- Pratt CA, Lemon SC, Fernandez ID, **Goetzel R**, Beresford SA, French SA, Stevens VJ, Vogt TM, Webber LS. Design characteristics of worksite environmental interventions for obesity prevention. *Obesity* 2007; 15(9): 2171–80.
- Rousculp MD, **Long SR**, **Wang S**, Schoenfeld MJ, Meadows ES. Economic burden of osteoporosis-related fractures in Medicaid. *Value in Health* 2007; 10(2): 144–52.



- Schulman KL**, Kohles J. Economic burden of metastatic bone disease in the U.S. *Cancer* 2007; 109(11): 2334–42.
- Thomas CP, Hodgkin D, Wallack SS, Martin T, Ritter GA, **Mark TL**. Mental health and substance abuse treatment prescription drugs: Lessons from a period of high spending growth. *Journal of Pharmaceutical Finance, Economics & Policy* 2007; 16(3): 67–83.
- Thomson Healthcare**. Bad debt, deductions, and utilization by payer. *Healthcare Financial Management* 2007; 61(8): 122–3.
- Vogeli C, Shields AE, Lee TA, **Gibson TB, Marder WD**, Weiss KB, Blumenthal D. Multiple chronic conditions: Prevalence, health consequences and implications for quality, care management, and costs. *Journal of General Internal Medicine* 2007; 22 Suppl 3: 391–5.*
- Wang C, Kereiakes DJ, Bae JP, McCollam P, He J, **Griffin B**. Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. *The Journal of Invasive Cardiology* 2007; 19(10): 431–6.*
- Wilson MG, **Goetzel RZ, Ozminkowski RJ**, DeJoy DM, Della L, Roemer EC, Schneider J, Tully KJ, White JM, Baase CM. Using formative research to develop environmental and ecological interventions to address overweight and obesity. *Obesity* 2007; 15(Suppl 1): 37S–47S.
- Wynn ML, **Chang S**, Peipins LA. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. *Journal of Women's Health* 2007; 16(7): 971–86.*
- Zhan C, Elixhauser A, Friedman B, **Houchens R**, Chiang YP. Modifying DRG-PPS to include only diagnoses present on admission: Financial implications and challenges. *Medical Care* 2007; 45(4): 288–91.

2006

- Baser O, Crown WH**, Pollicino C. Guidelines for selecting among different types of bootstraps. *Current Medical Research and Opinion* 2006; 22(4): 799–808.
- Baser O**, Gardiner J, Bradley C, Yuce H, Given B. Longitudinal analysis of censored medical cost. *Health Economics* 2006; 15(5): 513–525.
- Baser O**. Too much ado about propensity score models? Comparing methods of propensity score matching. *Value in Health* 2006; 9(6): 377–85.
- Buck JA, **Mark TL**. Datapoints: State-administered spending on mental health services by type of service. *Psychiatric Services* 2006; 57(1): 29.
- Burleigh E, Wang C, **Foster D, Heller S, Dunn D, Safavi K, Griffin B, Smith J**. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. *American Journal of Health System-Pharmacy* 2006; 63(20 Suppl 6): S23–9.*
- Chang S, Long SR**, Kutikova L, Bowman L, **Crown WH**, Lyman GH. Burden of pancreatic cancer and disease progression: Economic analysis in the US. *Oncology* 2006; 70(1): 71–80.



- Coben JH, Steiner CA, **Barrett M**, Merrill CT, Adamson D. Completeness of cause of injury coding in healthcare administrative databases in the United States, 2001. *Injury Prevention* 2006; 12(3): 199–201.
- Curkendall SM**, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan, Canada. *Annals of Epidemiology* 2006; 16(1): 63–70.*
- Curkendall SM**, Lanes S, de Luise C, Stang MR, Jones JK, She D, Goehring E Jr. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. *European Journal of Epidemiology* 2006; 21(11): 803–13.*
- Foley KA**, Denke MA, Kamal-Bahl S, Simpson Jr R, Berra K, Sajjan S, Alexander CM. The impact of physician attitudes and beliefs on treatment decisions: Lipid therapy in high-risk patients. *Medical Care* 2006; 44(5): 421–428.*
- Gibson TB, Mark TL**, Axelsen K, **Baser O**, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. *American Journal of Managed Care* 2006; 12(12 Spec No): SP11–9.*
- Gibson TB, Mark TL**, McGuigan KA, Axelsen K, **Wang S**. The effects of prescription drug copayments on statin adherence. *American Journal of Managed Care* 2006; 12(9): 509–17.*
- Goetzel R, Ozminkowski R**. Integrating to improve productivity. *Journal of Employee Assistance* 2006; 36(4): 25–28.
- Goetzel RZ, Ozminkowski RJ**. What's holding you back: Why should (or shouldn't) employers invest in health promotion programs for their workers? *North Carolina Medical Journal* 2006; 67(6): 428–30.
- Gosselein A, Pasho CL, Harley C, **Mark TL**, McKenzie RS. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: An analysis of four observational studies. *Clinical Therapeutics* 2006; 28(10): 1701–09.*
- Huse DM**, Castelli-Haley J, **Orsini LS, Lenhart G**, Abdalla JA. Patterns of initial pharmacotherapy for Parkinson's disease in the United States. *Journal of Geriatric Psychiatry and Neurology* 2006; 19(2): 91–97.*
- Huse DM, Song X, Ozminkowski RJ**, Maguire J, Williams SA, Borok GM, McDonough K. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: A data analysis. *Clinical Therapeutics* 2006; 28(9): 1425–42.
- Kohli M, Attard C, Lam A, **Huse D**, Cook J, Bourgault C, Alemao E, Yin D, Marentette M. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. *Pharmacoeconomics* 2006; 24: 815–830.
- Kutikova L, Bowman L, **Chang S, Long SR**, Arning M, **Crown WH**. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. *Leukemia & Lymphoma* 2006; 47(8): 1535–44.



- Larson MJ, **Miller K**, Fleming KJ. Antidepressant medication use in private insurance health plans, 2002. *Psychiatric Services* 2006; 57(2): 175.*
- Mark TL**, Buck J. Characteristics of U.S. youths with serious emotional disturbance: Data from the national health interview survey. *Psychiatric Services* 2006; 57(11): 1573–8.*
- Mark TL**, **Song X**, Vandivort-Warren R, Duffy S, Butler J, **Coffey R**, Schabert V. Characterizing substance abuse programs that treat adolescents. *Journal of Substance Abuse Treatment* 2006; 31(1): 59–65.
- Mark TL**, Vandivort-Warren R, **Montejano L**. Factors affecting detoxification readmission: Analysis of public sector data from three states. *Journal of Substance Abuse Treatment*. 2006; 31(4): 439–45.*
- Mucha L**, Masia NA, Axelsen KJ. Per-patient-per-month drug costs in Medicare Part D protected classes. *Pharmacoeconomics* 2006; 24 Suppl 3; 79–84.
- Mucha L**, **Stephenson J**, **Morandi N**, Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. *Gender Medicine* 2006; 3(4): 279–91.*
- Ozminkowski RJ**, Burton WN, **Goetzel RZ**, Maclean R, **Wang S**. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. *Journal of Occupational and Environmental Medicine* 2006; 48(2): 135–148.
- Ozminkowski RJ**, **Goetzel RZ**, **Shechter D**, Stapleton DC, **Baser O**, Lapin P. Predictors of preventive service use among Medicare beneficiaries. *Health Care Financing Review* 2006; 27(3): 5–23.*
- Ozminkowski RJ**, **Goetzel RZ**, Wang F, **Gibson TB**, **Shechter D**, Musich S, Bender J, Edington DW. The savings gained from participation in health promotion programs for Medicare beneficiaries. *Journal of Occupational and Environmental Medicine* 2006; 48(11): 1125–1132.
- Robinson RL, **Long SR**, **Chang S**, Able S, **Baser O**, Obenchain RL, Swindle RW. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: Analysis of administrative claims. *Journal of Managed Care Pharmacy* 2006; 12(1): 43–54.
- Safavi K**. Unintended consequences: Getting the most while avoiding the worst. *Journal of Healthcare Management* 2006; 51(6): 355–9.*
- Song X**, **Huse DM**, Williams SA, Borok GM, McDonough K, **Ozminkowski RJ**. A projection of the impact of lipid-lowering therapy on high-risk employee disability and medical costs. *Journal of Occupational and Environmental Medicine* 2006; 48(10): 1014–22.*
- Stallings SC, **Huse D**, Finkelstein SN, **Crown WH**, Witt WP, Maguire J, Hiller AJ, Sinskey AJ, Ginsburg GS. A framework to evaluate the economic impact of pharmacogenomics. *Pharmacogenomics* 2006; 7(6): 853–62.*



2005

- Berndt E, **Crown W**, Kallich J, **Long S**, **Song X**, Lyman GH. The impact of anaemia and its treatment on employee disability and medical costs. *Pharmacoeconomics* 2005; 23(2): 183–192.*
- Bray JW, Davis KL, Graver L, **Schroeder D**, Buck JA, Dilonardo J, Vandivort R. Mental health and substance abuse treatment utilization among individuals served by multiple public agencies in 3 states. *Journal of Behavioral Health Services & Research* 2005; 32(3): 282–93.*
- Coffey RM**, Andrews RM, Moy E. Racial, ethnic, and socioeconomic disparities in estimates of AHRQ patient safety indicators. *Medical Care* 2005; 43(3 Suppl): 148–57.*
- Collins JJ, Baase CM, Sharda CE, **Ozminkowski RJ**, Nicholson S, Billotti GM, Turpin RS, Olson M, Berger ML. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. *Journal of Occupational and Environmental Medicine* 2005; 47(6): 547–557.
- Duh MS, and **Mark TL**. Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy related anemia. *Expert Review of Pharmacoeconomics and Outcomes Research* 2005; 5(4): 383–394.
- Finkel S, Kozma C, **Long S**, Greenspan A, Mahmoud R, **Baser O**, Engelhart L. Risperidone treatment in elderly patients with dementia: Relative risk of cerebrovascular events versus other antipsychotics. *International Psychogeriatrics* 2005; 17(4): 1–13.*
- Gibson TB**, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: The long-term and short-term effects on use and expenditures. *Inquiry* 2005; 42: 293–310.*
- Gibson TB**, **Ozminkowski RJ**, **Goetzel RZ**. The effects of prescription drug cost sharing: A review of the evidence. *The American Journal of Managed Care* 2005; 11: 730–740.*
- Goetzel RZ**. Better outcomes through health and productivity management. *Managed Care* 2005; 14(10 Suppl): 28–36.*
- Goetzel RZ**, **Ozminkowski RJ**, Baase CM, Billotti GM. Estimating the return-on-investment from changes in employee health risks on the Dow Chemical Company's health care costs. *Journal of Occupational and Environmental Medicine* 2005; 47(8): 759–768.*
- Goetzel RZ**, **Ozminkowski RJ**, Villagra VG, Duffy J. Return on investment in disease management: A review. *Health Care Financing Review* 2005; 26(4): 1–19.
- Huse DM**, **Schulman K**, **Orsini L**, Castelli-Haley J, **Kennedy S**, **Lenhart G**. Burden of illness in Parkinson's disease. *Movement Disorders* 2005; 20(11): 1449–1454.*
- Kinchen KS, **Long S**, **Chang S**, Girts TK, Pantos B. The direct cost of stress urinary incontinence among women in a Medicaid population. *American Journal of Obstetrics & Gynecology* 2005; 193(6): 1936–1944.



- Kutikova L, Bowman L, **Chang S, Long SR**, Obasajua C, **Crown WH**. The economic burden of lung cancer and the associated costs of treatment failure in the United States. *Lung Cancer* 2005; 50(2): 143–154.
- Lyman GH, Berndt ER, Kallich JD, Erder MH, **Crown WH, Long SR**, Lee H, **Song X**, Finkelstein SN. The economic burden of anemia in cancer patients receiving chemotherapy. *Value in Health* 2005; 8(2): 149–156.
- Lynch WD, Chikamoto Y, Imai K, Lin TF, Kenkel DS, **Ozminkowski RJ, Goetzel RZ**. The association between health risks and medical expenditures in a Japanese corporation. *American Journal of Health Promotion* 2005; 19(3) Supplement: 238–248.
- Mark TL**, Buck JA. Components of spending for Medicaid mental health services, 2001. *Psychiatric Services* 2005; 56(6): 648.
- Mark TL, Coffey RM**, Vandivort-Warren R, Harwood HJ, King EC, MHA Spending Estimates Team. U.S. spending for mental health and substance abuse treatment, 1991–2001. *Health Affairs* 2005; Jan–Jun Suppl Web Exclusives: W5–133–W5–142.
- Mark TL**, McKenzie RS, Fastenau J, Piech CT. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. *Current Medical Research and Opinion* 2005; 21(9): 1347–1354.*
- Mark TL, Ozminkowski R**. What will be the impact of the Medicare doughnut hole? *Drug Benefit Trends* 2005; 17(6): 254–261.
- Matson Koffman DM, **Goetzel RZ**, Anwuri VV, Shore KK, Orenstein D, LaPier T. Heart healthy and stroke free: successful business strategies to prevent cardiovascular disease. *American Journal of Preventative Medicine* 2005; 29(5 Suppl 1): 113–21.
- Montejano LB, Goetzel RZ, Ozminkowski RJ**. Impact of bipolar disorder on employers: Rationale for workplace interventions. *Disease Management and Health Outcomes* 2005; 13(4): 267–280.
- Nicholson S, Pauly MV, Polsky D, Baase CM, Billotti GM, **Ozminkowski RJ**, Berger ML, Sharda CE. How to present the business case for healthcare quality to employers. *Applied Health Economics and Health Policy* 2005; 4(4): 209–218.
- Orsini L**, Rousculp MD, **Long SR, Wang S**. Health care utilization and expenditures in the United States: A study of osteoporosis-related fractures. *Osteoporosis International* 2005; 16: 359–371.
- Rhoads GG, **Orsini LS, Crown W, Wang S**, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. *Journal of Occupational and Environmental Medicine* 2005; 47(5): 447–452.
- Russo PA, Smith MW**, Namjoshi M. Health care costs for schizophrenia patients started on olanzapine versus risperidone. *American Journal of Health-System Pharmacy* 2005; 62(6): 610–615.
- Slade EP, Salkever DS, Rosenheck R, Swanson J, Swartz M, Shern D, Gallucci G, Harding C, **Palmer L, Russo P**, Hough RL, Barrio C, Garcia P. Cost-sharing requirements and access to mental health care among medicare enrollees with schizophrenia. *Psychiatric Services* 2005; 56(8): 960–6.



vanVonno CJ, **Ozminkowski RJ**, **Smith MW**, Thomas EG, Kelley D, **Goetzel R**, Berg GD, Jain SK, Walker DR. What can a pilot congestive heart failure disease management program tell us about likely return on investment? A case study from a program offered to federal employees. *Disease Management* 2005; 8(6): 346–360.

2004

- Baker LC, Phibbs CS, Guarino C, **Supina D**. Within-year variation in hospital utilization and its implications for hospital costs. *Journal of Health Economics* 2004; 23: 191–211.
- Baser O**, Bradley C, Gardiner J, Given B. Estimation from censored medical cost. *Biometrical Journal* 2004; 46: 351–363.
- Chang S**, **Long SR**, Kutikova L, Bowman L, Finley D, **Crown WH**, Bennett CL. Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. *Journal of Clinical Oncology* 2004; 22(17): 3524–3530.
- Crown WH**, Berndt ER, **Baser O**, Finkelstein SN, Witt WP, **Maguire J**, Haver KE. Benefit plan design and prescription drug utilization among asthmatics: Do patient copayments matter? *Frontiers in Health Policy Research* 2004; 7: 95–127.
- Crown WH**, Bresnahan BW, **Orsini LS**, **Kennedy S**, Leonardi C. The burden of illness associated with psoriasis: Cost of treatment with systemic therapy and phototherapy in the US. *Current Medical Research and Opinion* 2004; 20(12): 1929–1936.
- Curkendall SM**, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. *Journal of Clinical Psychiatry* 2004; 65(5): 715–20.*
- Finkelstein E, Bray J, Larson MJ, **Miller K**, Tompkins C, Keme A, Manderscheid R. Prevalence of, and payments for, mental health and substance abuse disorders in public and private health plans. SAMHSA/CMHS (Center for Mental Health Services) Mental Health, United States 2002, 165–185, 2004.
- Goetzel RZ**, **Long SR**, **Ozminkowski RJ**, **Hawkins K**, **Wang S**, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. *Journal of Occupational and Environmental Medicine* 2004; 46(4): 398–412.
- Hansen LG**. Is the glass half full or half empty? Patient dynamics underlying marketshare. *Product Management Today* 2004; 15(10): 37–39.
- Kinchen KS, **Long S**, **Orsini L**, **Crown W**, Bump R. Healthcare utilization among women who undergo surgery for stress urinary incontinence. *International Urogynecology Journal of Pelvic Floor Dysfunction* 2004; 15(3): 154–159.*
- Mark TL**. Are medications for alcoholism underutilized? An analysis of private sector and Medicaid claims. *Drug Benefit Trends* 2004; 16(3): 154–158.*
- Mark TL**. Preferences among antipsychotic medications given particular clinical scenarios. *Schizophrenia Research* 2004; 66(1): 71–73.*



- Mark TL, Coffey RM.** The decline in receipt of substance abuse treatment by the privately insured, 1992–2001. *Health Affairs* 2004; 23(6): 157–162.*
- Mark TL,** Swait J. Using stated preference and revealed preference modeling to evaluate prescribing decisions. *Health Economics* 2004; 13(6): 563–573.
- Orsini L,** Limpa-Amara S, **Crown WH,** Stanford RH, and Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs. montelukast. *Annals of Allergy, Asthma and Immunology* 2004; 92(5): 523–529.*
- Ozminkowski RJ, Goetzel RZ, Chang S, Long S.** The application of two health and productivity instruments at a large employer. *Journal of Occupational and Environmental Medicine* 2004; 46(7): 635–648.
- Ozminkowski RJ, Goetzel RZ,** Santoro J, Saenz BJ, Eley C, Gorsky B. Estimating risk reduction required to break even in a health promotion program. *American Journal of Health Promotion* 2004; 18(4): 316–325.
- Ozminkowski RJ, Marder WD, Hawkins K, Wang S,** Stallings SC, Finkelstein SN, Sinsky AJ, Wierz D. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. *Clinical Therapeutics* 2004; 26(8): 1341–1354.*
- Papatheofanis F, Fahrback K, **Mark TL,** Chiang T, Frame D, Suruki RY, Scheye R, Drielick M, Nalysnyk L. A pooled analysis of observational data evaluating usage and clinical outcomes of erythropoietic agents. *Journal of Clinical Oncology* 2004; 22(14S): 6114.*
- Russell J, **Hawkins K, Ozminkowski R, Orsini L, Crown W, Kennedy S,** Finkelstein S, Berndt E, Rush J. Cost consequences of treatment-resistant depression. *Journal of Clinical Psychiatry* 2004; 65(3): 341–347.
- Salkever DS, Slade EP, Karakus M, **Palmer L, Russo PA.** Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables. *The Journal of Nervous and Mental Disease* 2004; 192(2): 119–128.*
- Stang PE, **Crown WH, Bizier R,** Chatterton ML, White R. The family impact and costs of migraine. *The American Journal of Managed Care* 2004; 10(5): 313–320. (Kenneth M. Langa, MD, wrote an editorial about this article that was titled “An Illness in the Family: Accounting for the Complex Effects of Illness on Other Family Members” and was published in the same issue of *JOEM*.)
- Turpin RS, **Ozminkowski RJ,** Sharda CE, Collins JJ, Berger ML, Billotti GM, Baase CM, Olson MJ, Nicholson S. Reliability and validity of the Stanford Presenteeism Scale. *Journal of Occupational and Environmental Medicine* 2004; 46(11): 1123–1133.



2003

- Barrio C, Yamada AM, Atuel H, Hough RL, Yee S, Berthot B, **Russo PA**. A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders. *Schizophrenia Research* 2003; 60(2–3): 259–69.*
- Baser O**, Bradley C, Gardiner J, Given B. Testing and correcting non-random selection bias due to censoring: An application to medical costs. *Health Services and Outcomes Research Methodology* 2003; 4(2): 93–107.
- Bradley CJ, Given C, **Baser O**, Gardiner J. Influence of surgical and treatment choices on the cost of breast cancer care. *European Journal of Health Economics* 2003; 4: 96–101.
- Brooks J, Clark MA, **Crown B**, Davey P, Hutchins D, Martin B, Motheral B, Stang P. A checklist for retrospective database studies—Report of the ISPOR Task Force on Retrospective Databases. *Value in Health* 2003; (6)2: 90–97.
- Cohen FJ, Neslusan CA, **Conklin JE**, **Song X**. Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. *Diabetes Care* 2003; 26(6): 1847–1851.*
- Crown WH**, Olufade A, **Smith MW**, Nathan R. Seasonal versus perennial allergic rhinitis: Drug and medical resource utilization patterns. *Value in Health* 2003; 6(4): 448–456.*
- Goetzel RZ**, **Hawkins K**, **Ozminkowski RJ**, **Wang S**. The health and productivity cost burden of the ‘top 10’ physical and mental health conditions affecting six large U.S. employers in 1999. *Journal of Occupational and Environmental Medicine* 2003; 45(1): 5–14.
- Goetzel RZ**, **Ozminkowski RJ**, **Long SR**. Development and reliability analysis of the work productivity short inventory (WPSI) instrument measuring employee health and productivity. *Journal of Occupational and Environmental Medicine* 2003; 45(7): 743–762.
- Guo JJ, **Curkendall SM**, Jones JK, Fife D, Goehring E, She D. Impact of cisapride label changes on codispensing of contraindicated medications. *Pharmacoepidemiology and Drug Safety* 2003; 12(4): 295–301.*
- Harwood HJ, **Mark TL**, McKusick DR, **Coffey RM**, King EC, Genuardi JS. National spending on mental health and substance abuse treatment by age of clients, 1997. *The Journal of Behavioral Health Services & Research* 2003; 30(4): 433–43.
- Kinchen KS, **Long S**, **Orsini L**, **Crown W**, Swindle R. A retrospective claims analysis of the direct costs of stress urinary incontinence. *International Urogynecology Journal of Pelvic Floor Dysfunction* 2003; 14(6): 403–411.
- Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, **Russo PA**, **Crown WH**. The schizophrenia care and assessment program health questionnaire (SCAP_HA): An instrument to assess outcomes of schizophrenia care. *Schizophrenia Bulletin* 2003; 29(2): 247–256.
- Mark TL**, Buck JA, Dilonardo JD, **Coffey RM**, Chalk M. Medicaid expenditures on behavioral health care. *Psychiatric Services* 2003; 54(2): 188–194.



- Mark TL, Coffey RM.** What drove private health insurance spending on mental health and substance abuse care, 1992–1999? *Health Affairs* 2003; 22(1): 165–72.
- Mark TL, Dilonardo JD, Chalk M, Coffey R.** Factors associated with the receipt of treatment following detoxification. *Journal of Substance Abuse Treatment* 2003; 24(4): 299–304.*
- Mark TL, Kranzler HR, Poole VH, Hagen CA, McLeod C, Crosse S.** Barriers to the use of medications to treat alcoholism. *American Journal on Addictions* 2003; 12(4): 281–294.*
- Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S.** Physicians' opinions about medications to treat alcoholism. *Addiction* 2003; 98(5): 617–626.*
- Mark TL, Kranzler HR, Song X.** Understanding US addiction physicians' low rate of naltrexone prescription. *Drug and Alcohol Dependence* 2003; 71(3): 219–228.*
- Mark TL, Ozminkowski RJ, Kirk A, Ettner SL, Drabek J.** Risk adjustment for people with chronic conditions in private sector health plans. *Medical Decision Making* 2003; 23(5): 397–405.
- Mark TL, Palmer LA, Russo PA, Vasey J.** Examination of treatment pattern differences by race. *Mental Health Services Research* 2003; 5(4): 241–250.*
- Mark TL, Swait J.** Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications. *Value in Health* 2003; 6(4): 474–482.*
- Mark TL.** The costs of treating persons with depression and alcoholism compared with depression alone. *Psychiatric Services* 2003; 54(8): 1095–1097.
- Ozminkowski RJ, Goetzel RZ, Long SR.** A validity analysis of the work productivity short inventory (WPSI) instrument measuring employee health and productivity. *Journal of Occupational and Environmental Medicine* 2003; 45(11): 1183–1195.
- Ozminkowski RJ, Mark TL, Goetzel RZ, Blank D, Walsh JM, Cangianelli L.** Relationships between urinalysis testing for substance use, medical expenditures, and the occurrence of injuries at a large manufacturing firm. *The American Journal of Drug and Alcohol Abuse* 2003; 29(1): 151–167.*
- Stull DE, Rempher K, Jairath N, Kapustin J.** The utility of multidimensional assessments of physical health in patient care. *AACN Clinical Issues* 2003; 14(2): 251–260.
- Teich J, **Buck J, Graver L, Schroeder D, Zheng D.** Utilization of public mental health services by children with serious emotional disturbances. *Administration and Policy in Mental Health* 2003; 30(6): 523–34.*
- Thomas P, **Goetzel RZ, Ozminkowski RJ, Kassabian VS, Schutt DC.** Results of a men's urological health screening program at Lockheed Martin Aeronautical Systems. *Disease Management Health Outcomes* 2003; 11(3): 181–189.*



2002

- Berndt E, **Crown W**. Labor force activity in cancer patients with anemia. *Quality of Life in Oncology* 2002; 5(4): 10–13.*
- Chawla A**, Swindle R, **Long S**, **Kennedy S**, Sternfeld B. Premenstrual dysphoric disorder: Is there an economic burden of illness? *Medical Care* 2002; 40(11): 1101–1112.
- Crown W**, Finkelstein S, Berndt E, **Ling D**, **Poret A**, Rush J, Russell J. The impact of treatment-resistant depression on healthcare utilization and costs. *Journal of Clinical Psychiatry* 2002; 63(11): 963–971.*
- Crystal-Peters J**, **Chang S**, **Long S**, Tretiak R. Health care expenditures of patients with major depressive disorder and post traumatic stress disorder. *European Psychiatry* 2002; 17(Suppl. 1): 150.*
- Crystal-Peters J**, Neslusan C, **Crown WH**, **Torres A**. Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma related hospitalizations and emergency room visits. *The Journal of Allergy and Clinical Immunology* 2002; 109(1): 57–62.*
- Crystal-Peters J**, Neslusan CA, **Smith MW**, Togias A. Health care costs of allergic rhinitis-associated conditions vary with allergy season. *Annals of Allergy, Asthma & Immunology* 2002; 89(5): 457–462.
- Goetzel RZ**, **Ozminkowski RJ**, Bruno JA, Rutter KR, Isaac F, **Wang S**. The long term impact of Johnson & Johnson's Health & Wellness program on employee health risks. *Journal of Occupational and Environmental Medicine* 2002; 44(5): 417–424.
- Goetzel RZ**, **Ozminkowski RJ**, **Schutt DC**. The value of pharmaceuticals—Some direction for employers. *Employee Benefits Journal* 2002; 27(3): 31–35.
- Goetzel RZ**, **Ozminkowski RJ**, Sederer LI, **Mark TL**. The business case for quality mental health services: Why employers should care about the health and well-being of their employees. *Journal of Occupational and Environmental Medicine* 2002; 44(4): 320–330.
- Goetzel RZ**, **Ozminkowski RJ**, Sederer LI, **Mark TL**. Working with depression, part I: The case for quality mental health services. *Business and Health* 2002; August 1.
- Goetzel RZ**, **Ozminkowski RJ**, Sederer LI, **Mark TL**. Working with depression, part II: Finding and funding effective treatment. *Business and Health* 2002; August 1.
- Goetzel RZ**, **Ozminkowski RJ**, **Yuhasz L**. Health and productivity management: What does this have to do with health promotion? Adapted by Wolf Kirstein, *Health Promotion Global Perspectives* 2002; 4(2): 2–3.
- Goetzel RZ**, **Ozminkowski RJ**. Program evaluation. Chapter 5, *Health Promotion in the Workplace*, Third Edition, Michael P. O'Donnell (ed.), Albany, NY: Delmar/Thomson Learning, 2002.



- Mark HH, Robbins KP, **Mark TL**. Axial length in applanation tonometry. *Journal of Cataract and Refractive Surgery* 2002; 28(3): 504–6.
- Mark TL**, Dilonardo JD, Chalk M, **Coffey RM**. Trends in inpatient detoxification services: 1992–1997. *Journal of Substance Abuse Treatment* 2002; 23(4): 253–260.*
- Mark TL**, **Dirani R**, Slade E, **Russo PA**. Access to new medications to treat schizophrenia. *Journal of Behavioral Health Services & Research* 2002; 29(1): 15–29.*
- McKusick DR, **Mark TL**, King EC, **Coffey RM**, Genuardi J. Trends in mental health insurance benefits and out-of-pocket spending. *The Journal of Mental Health Policy and Economics* 2002; 5(2): 21–31.
- Ozminkowski RJ**, **Ling D**, **Goetzel RZ**, Bruno JA, Rutter KR, Isaac F, **Wang S**. Long-term impact of Johnson & Johnson’s Health & Wellness program on health care utilization and expenditures. *Journal of Occupational and Environmental Medicine* 2002; 44(1): 21–29.
- Poret AW**, **Ozminkowski RJ**, **Goetzel R**, **Pew JE**, **Balent J**. Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. *Disease Management* 2002; 5(2): 95–107.
- Russo P**, **Smith MW**, **Dirani R**, Namjoshi M, Tohen M. Pharmacotherapy patterns in the treatment of bipolar disorder. *Bipolar Disorder* 2002; 4(6): 366–377.*
- Sternfeld B, Swindle R, **Chawla A**, **Long S**, **Kennedy S**. Severity of premenstrual symptoms in a health maintenance organization population. *Obstetrics & Gynecology* 2002; 99(6): 1014–1024.*
- Thomas P, **Goetzel RZ**, **Ozminkowski RJ**, Kassabian VS, **Schutt DC**. If men won’t go to doctors... *Business and Health* 2002; June 19.
- Wan GJ, **Crown WH**, Berndt ER, Finkelstein SN, **Ling D**. Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety. *International Journal of Clinical Practice* 2002; 56(6): 434–439.

2001

.....

- Burwell B**. Medicaid long-term care expenditures in fiscal year 2000. *Gerontologist* 2001; 41(5): 687–691.
- Chawla AJ**, Hatzmann MH, **Long SR**. Developing performance measures for prescription drug management. *Health Care Financing Review* 2001; 22(3): 71–84.
- Crown W**, Treglia M, **Meneades L**, **White A**. Long-term costs of treatment for depression: Impact of drug selection and guideline adherence. *Value in Health* 2001; 4(4): 295–307.
- Crown W**, Wan G, Berndt E, Finkelstein S, **Ling D**. Differences in health care expenditures among patients treated for depression with or without anxiety. *Value in Health* 2001; 4(2): 148.
- Crown W**. Antidepressant selection and economic outcome: A review of methods and studies from clinical practice. *British Journal of Psychiatry* 2001; 179(Suppl. 42): s18–s22.



- Crown W.** Economic status of the elderly. In R. Binstock and L. George (Eds.), *Handbook of Aging and the Social Sciences*. New York: Academic Press, 2001.
- Crown WH, Neslusan C, Russo PA, Holzer S, Ozminkowski R, Croghan T.** Hospitalization and total medical costs for privately insured persons with schizophrenia. *Administration and Policy in Mental Health* 2001; 28(5): 335–351.
- Gibson TB, McLaughlin CG, Smith DG.** Cost-sharing for prescription drugs. *The Journal of the American Medical Association* 2001; 285(18): 2328–9.
- Goetzel RZ, Guindon AM, Turshen IJ, Ozminkowski RJ.** Health and productivity management: Establishing key performance measures, benchmarks, and best practices. *Journal of Occupational and Environmental Medicine* 2001; 43(1): 10–17.
- Goetzel RZ, Ozminkowski RJ, Ascianto AJ, Chouinard P, Barrett M.** Survey of Koop Award winners: Life-cycle insights. *The Art of Health Promotion* 2001; 5(2).
- Goetzel RZ, Ozminkowski RJ, Schutt DC.** Pharmaceuticals—cost or investment? Chapter 36 in *Employee Benefit Issues: The Multiemployer Perspective*. Volume 43 (2001), Brookfield, WI: International Foundation of Employee Benefit Plans.
- Goetzel RZ.** A corporate perspective: Reflections from the economic buyer of health promotion programs (introduction to the Corporate Perspectives section of special issue). *American Journal of Health Promotion* 2001; 15(5): 357.
- Goetzel RZ.** The financial impact of health promotion and disease prevention programs—Why is it so hard to prove value? (introduction to special issue). *American Journal of Health Promotion* 2001; 15(5): 277–80.
- Jones JK, Fife D, **Curkendall SM**, Goehring E, Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. *JAMA* 2001; 286(13): 1607–9.*
- Joseph AK, **Mark TL**, Mueller C. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by Medicare. *Dermatologic Surgery* 2001; 27(11): 955–9.
- Ling D**, Bresnahan B, **White A**, Neslusan C, **Crown W**. Risk of hospitalization for patients with bipolar disorder. *Value in Health* 2001; 4(2): 144.*
- Mark TL, Coffey RM.** Studying the effects of health plan competition: Are available data resources up to the task? *Health Services Research* 2001; 36(1 Pt 2): 253–275.
- Mark TL**, Woody GE, **Juday T**, Kleber HD. The economic costs of heroin addiction in the United States. *Drug and Alcohol Dependence* 2001; 61(2): 195–206.
- McCulloch JM, **Ozminkowski RJ**, Cuffel B, Dunn RL, Goldman W, Kelleher D, **Comporato A**. Analysis of a managed psychiatric disability program. *Journal of Occupational and Environmental Medicine* 2001; 43(2): 101–109.
- Merrick NJ, Houchens R**, Tillisch S, Berlow B, Landon C. Quality of hospital care of children with asthma: Medicaid versus privately insured patients. *Journal of Health Care for the Poor and Underserved* 2001; 12(2): 192–207.



- Ozminkowski RJ, Goetzel RZ, Crown WH.** Productivity measurement for pharmacoeconomic and outcomes research studies. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) News* 2001; December 15.
- Ozminkowski RJ, Goetzel RZ.** Getting closer to the truth: Overcoming research challenges when estimating the financial impact of worksite health promotion programs. *American Journal of Health Promotion* 2001; 15(5): 289–295.
- Ozminkowski RJ, Mark T, Cangianelli L, Walsh JM, Davidson R, Blank D, Flegel RR, Goetzel RZ.** The cost of on-site vs. off-site workplace urinalysis testing for illicit drug use. *Health Care Manager* 2001; 20(1): 59–69.
- Poret AW, Neslusan C, Ricci JF, Wang S, Khan ZM, Kwong JW.** Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants. *Value in Health* 2001; 4(5): 362–369.
- Wasserman J, Boyce-Smith G, Hopkins DS, Schabert V, Davidson MB, Ozminkowski RJ, Albright A, Kennedy S.** A comparison of diabetes patients' self-reported health status with hemoglobin A1c test results in 11 California health plans. *Managed Care* 2001; 10(3): 58–70.*

2000

- Anderson DR, Whitmer RW, **Goetzel RZ, Ozminkowski RJ, Dunn RL, Wasserman J, Serxner S;** Health Enhancement Research Organization (HERO) Research Committee. The relationship between modifiable health risks and group-level health care expenditures. *American Journal of Health Promotion* 2000; 15(1): 45–52.
- Crown W.** Antidepressant use and clinical and economic outcomes in a primary care psychiatry center in Spain: A review of a naturalistic study. J. Guimón and N. Sartorius (eds) *Manage or Perish?* Kluwer Academic Publishers, 2000.
- Crown W.** Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression. *Acta Psychiatrica Scandinavica* 2000; 101(Suppl. 403): 62–66.
- Crown W.** Productivity measurement in pharmaceutical studies. *Drug Benefit Trends* 2000; 12(2): 5–8.
- Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC.** The cost of productivity losses associated with allergic rhinitis. *The American Journal of Managed Care* 2000; 6(3): 373–378.
- Dilonardo J, Chalk M, **Mark TL, Coffey RM,** CSAT/CMHS Spending Estimates Team. Recent trends in the financing of substance abuse treatment: Implications for the future. *Health Services Research* 2000; 35(5 Pt 3): 60–71.
- Dubois RW, **Chawla AJ, Neslusan CA, Smith MW,** Wade S. Explaining drug spending trends: Does perception match reality? *Health Affairs* 2000; 19(2): 231–239.



- Ettner SL, Frank RG, **Mark TL, Smith MW**. Risk adjustment of capitation payments to behavioral health care carve-outs: How well do existing methodologies account for psychiatric disability? *Health Care Management Science* 2000; 3(2): 159–169.
- Goetzel RZ, Ozminkowski RJ**. Health and productivity management: Emerging opportunities for health promotion professionals for the 21st century. *American Journal of Health Promotion* 2000; 14(4): 211–214.
- Goetzel RZ, Ozminkowski RJ, Del Rosso G, Schutt DC**. Are drugs a cost or an investment? *Business & Health* 2000; June: 39–45.
- Goetzel RZ, Ozminkowski RJ, Meneades L, Stewart M, Schutt DC**. Pharmaceuticals—Cost or investment? An employer's perspective. *Journal of Occupational and Environmental Medicine* 2000; 42(4): 338–351.
- Goetzel RZ, Ozminkowski RJ**. Disease management as a part of total health and productivity management. *Disease Management & Health Outcomes* 2000; 8(3): 121–128.
- Leutzinger JA, **Ozminkowski RJ**, Dunn RL, **Goetzel RZ**, Richling DE, Stewart M, Whitmer RW. Projecting future medical care costs using four scenarios of lifestyle risk rates. *American Journal of Health Promotion* 2000; 15(1): 35–44.
- Mark TL, Coffey RM**, King E, Harwood H, McKusick D, Genuarid J, Dilonardo J, Buck J. Spending on mental health and substance abuse treatment, 1987–1997. *Health Affairs* 2000; 19(4): 108–120.
- Ozminkowski R, Wang S, Marder WD, Azzolini J, Schutt D**. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. *Pharmacoeconomics* 2000; 18(3): 253–264.
- Ozminkowski R., Wang S, Marder WD, Azzolini J**. Short-run associations between medical care expenditures and adherence to clinical practice guideline-based measures for diabetes. *Value in Health* 2000; 3(s1): 29–38.
- Ozminkowski RJ, Goetzel RZ, Smith MW**, Cantor RI, Shaughnessy A, Harrison M. The impact of the Citibank, N.A., health management program on changes in employee health risks over time. *Journal of Occupational and Environmental Medicine* 2000; 42(5): 502–511.
- Shea D, **Russo P**, Smyer M. Use of mental health services by persons with a mental illness in nursing facilities: Initial impacts of OBRA87. *Journal of Aging and Health* 2000; 12(4): 560–577.*
- Siddique R, **Neslusan CA, Crown WH, Crystal-Peters J**, Sloan S, Farup C. A national inpatient cost estimate of percutaneous endoscopic gastrostomy (PEG)-associated aspiration pneumonia. *The American Journal of Managed Care* 2000; 6(4): 490–496.
- Wasserman J**, Whitmer RW, Bazzarre TL, **Kennedy ST, Merrick N, Goetzel RZ, Dunn RL, Ozminkowski RJ**, HERO Research Committee. Gender-specific effects of modifiable health risk factors on coronary heart disease and related expenditures. *Journal of Occupational and Environmental Medicine* 2000; 42(11): 1060–1069.
- Xuan J, Duong P, **Russo P**, Lacey MJ, Fu Q, Wong B. The economic burden of congestive heart failure in a managed care population. *The American Journal of Managed Care* 2000; 6(6): 693–700.



1999

- Adams EK, **Graver L**. Medicaid providers of children's preventive services, 1989 and 1992. *HCFA Review* 1999; 19(4).
- Claxton AJ, **Chawla AJ, Kennedy S**. Absenteeism among employees treated for depression. *Journal of Occupational and Environmental Medicine* 1999; 41(7): 605–611.
- Crown W**. Familiar policy issues, Australian style. Book review for *The Gerontologist*. 1999; 39(2): 239–242.
- Cuffel B**, Wamboldt M, Borish L, **Kennedy S, Crystal-Peters J**. Economic consequences of comorbid depression, anxiety, and allergic rhinitis. *Psychosomatics* 1999; 40(6): 491–496.
- Dunn RL**, Donaghue JM, **Ozminkowski RJ**, Hylan TR. Longitudinal patterns of antidepressant prescribing in primary care in the UK: Comparison with treatment guidelines. *Journal of Psychopharmacology* 1999; 13(2): 136–143.*
- Experton B, **Ozminkowski RJ**, Pearlman DN, Li Z, Thompson SK. How does managed care manage the frail elderly? The case of hospital readmissions in fee-for-service versus HMO systems. *American Journal of Preventive Medicine* 1999; 16(3): 163–172.*
- Gage B**, Moon M, Chi S. State-level variation in Medicare spending. *Health Care Finance Review* 1999; 21(2): 85–98.
- Goetzel RZ, Juday T, Ozminkowski RJ**. What's the ROI: A systematic review of return on investment studies of corporate health and productivity management initiatives. *AWHP's Worksite Health* 1999; 7: 12–19.
- Goetzel RZ, Ozminkowski RJ**. Health and productivity management: An emerging business paradigm. *Employee Benefits News* 1999; October 15.
- Goetzel RZ, Ozminkowski RJ**. Health productivity management assists benefits business strategy. *Employee Benefits News* 1999; October 15.
- Hylan T, **Crown W, Meneades L**, Heiligenstein J, Melfi C, Croghan T, Buesching D. SSRI antidepressant drug use patterns in the naturalistic setting: A multivariate analysis. *Medical Care* 1999; 37(4): AS36–AS44.*
- Hylan T, **Meneades L, Crown W**, Sacristan J, Gilaberte I, Montejo AL. SSRI antidepressant use patterns and their relation to clinical global impression scores: A naturalistic study. *Journal of Affective Disorders* 1999; 52: 111–119.*
- Krinsky T, Shechter D**. CCHRI/HEDIS reporting year 1998: Major changes. *Journal of the California Health Information Association* 1999; Feb.
- Krinsky T**. Keeping you on your toes: Podiatric surgery modifiers for hospital outpatient. *Journal of the California Health Information Association* 1999; Mar.



- Mark HD, **Mark TL**. School based vision screening: Determinants of nonresponse following referral. *Journal of School Health* 1999; 69(1): 35–38.
- Mark TL**. The rationale for and consequences of nonprofit and for-profit ownership conversion. *Health Services Research* 1999; 34(1): 83–102.
- Neslusan CA**, Hylan TR, **Dunn RL**, Donoghue J. Controlling for systematic selection in retrospective analyses: An application to fluoxetine and sertraline prescribing in the United Kingdom. *Value in Health* 1999; 2(6): 435–445.
- Ozminkowski RJ**, **Dunn RL**, **Goetzel RZ**, Cantor R, Murnane J, **Harrison M**. A return on investment evaluation of the Citibank, N.A., health management program. *American Journal of Health Promotion* 1999; 14(1): 31–43.
- Ozminkowski RJ**, **Goetzel RZ**. Response from the authors: The value of ROI research. *American Journal of Health Promotion* 1999; 14(1): 46.
- Sacristan J, Gilaberte I, Montejo A, Garzon B, **Crown W**, Hylan T. Costos del tratamiento con nuevos antidepressivos en la practica clinica habitual. *Atención Primaria* 1999; 23(1): 15–25.
- Stafford RS, Saglam D, Causino N, Starfield B, Culpepper L, **Marder WD**, Blumenthal D. Trends in adult visits to primary care physicians in the United States. *Archives of Family Medicine* 1999; 8(1): 26–32.*
- Treglia M, **Neslusan CA**, **Dunn RL**. The effect of initiating therapy on fluoxetine and dothiepin on health care resource utilization in the United Kingdom. *International Journal of Psychiatry and Clinical Practice* 1999; 3: 23–30.*

1998

- Barnes CA**, **Krinsky T**. Classification systems, casemix, and data quality: Implications for international management and research applications. *Casemix Quarterly, The Scientific Journal of Patient Classification Systems/Europe* 1998; 1(2) Italy.
- Conklin J**. Surmounting the challenges in health plans' performance data. In *Creating Consumer Choice in Healthcare, Measuring and Communicating Health Plan Performance Information*. Academy of Consumer-Choice Health Purchasing Groups, Institute for Health Policy Solutions. Health Administration Press, a division of the Foundation of the American College of Healthcare Executives, 1998: 65–71.
- Croghan T, Melfi C, **Crown W**, **Chawla A**. Cost-effectiveness of antidepressant medications. *The Journal of Mental Health Policy and Economics* 1998; 1: 109–117.
- Croghan T, Obenchain R, **Crown W**. What does treatment of depression really cost? *Health Affairs* 1998; 17(4): 198–208.
- Crown W**, Hylan T, **Meneades L**. Antidepressant selection and use and healthcare expenditures: An empirical approach. *Pharmacoeconomics* 1998; 13(4): 435–448.



- Crown W**, Obenchain R, Engelhart L, **Lair T**, Buesching D, Croghan T. The application of sample selection models to outcomes research: The case of evaluating the effects of antidepressant therapy on resource utilization. *Statistics in Medicine* 1998; 17: 1943–1958.
- Crown W**. Social security and employment policy. Book review for *The Gerontologist* 1998; 38(1): 132–135.
- Crown W**. *Statistical Models for the Behavioral Sciences*. Praeger Publishers, 1998.
- Crystal-Peters J**, **Ozminkowski RJ**, **Marder WD**. Using claims data to identify factors that facilitate cost-containment and disease management. *Continuing Education Series in Pharmacy & Managed Care* 1998; 5(4): 4–6.
- Doty P, **Jackson ME**, **Crown W**. The impact of female caregivers' employment status on patterns of formal and informal care. *The Gerontologist* 1998; 38: 331–341.
- Dunn RL**, Donaghue JM, **Ozminkowski RJ**, Hylan TR. Selective serotonin reuptake inhibitor antidepressant prescribing in primary care in the United Kingdom: A longitudinal analysis. *Primary Care Psychiatry* 1998; 4(3): 141–148.
- Elixhauser A, Steiner C, Harris D, **Coffey R**. Comorbidity measures for use with administrative data. *Medical Care* 1998; 36(1): 8–27.
- Fox KP**, Bachman SS, **Burwell B**. Encounter data and Medicaid managed care: Reasonable expectations for information in the new world. In Davidson, S.M. and S.A. Somers (eds.). *Remaking Medicaid: Managed Care for the Public Good*. San Francisco, CA: Jossey-Bass Publishers, 1998.
- Gavin NI, Adams EK, Herz EJ, **Chawla AJ**, Ellwood M, Hill I, Zimmerman B, **Wasserman J**. The use of EPSDT and other preventive and curative health care services by children enrolled in Medicaid: The impact of the Omnibus Budget Reconciliation Act of 1989. *The Milbank Quarterly* 1998; 76(2): 207–250.
- Goetzel RZ**, Anderson DA, Whitmer RW, **Ozminkowski RJ**, **Dunn RL**, **Wasserman J**, Health Enhancement Research Organization (HERO) Research Committee. The relationship between modifiable health risks and health care expenditures. An analysis of the multi-employer HERO health risk and cost database. *Journal of Occupational and Environmental Medicine* 1998; 40(10): 843–854.
- Goetzel RZ**, **Dunn RL**, **Ozminkowski RJ**, Satin K, Whitehead D, Cahill K. Differences between descriptive and multivariate estimates of the impact of Chevron Corporation's Health Quest Program on medical expenditures. *Journal of Occupational and Environmental Medicine* 1998; 40(6): 538–545.
- Goetzel RZ**, **Guindon A**, Humphries L, Newton P, Turshen J, Webb R. Health and productivity management: Consortium benchmarking study best practice report. *American Productivity and Quality Center International Benchmarking Clearinghouse*, Houston, TX, July 1998. Available through <http://www.apqc.org>.
- Goetzel RZ**, Jacobson BH, Aldana SG, Vardell K, Yee L. Health care costs of worksite health promotion participants and non-participants. *Journal of Occupational and Environmental Medicine* 1998; 40(4): 341–346.



- Goetzel RZ**, Webb R. The health and productivity management consortium benchmarking study. Chapter in the *Guide to Managed Care Strategies: 1999*, Joseph Burns and Laura Northup (eds.), New York: Faulkner & Gray, Inc., 1998.
- Goetzel RZ**. Developing normative and benchmark data for health and productivity management: Results of a multi-employer benchmarking study. NASA Occupational Health Conference, Lake Buena Vista, FL, August 1998. Proceedings published by NASA—CP-99-20843: 57–64.
- Herz EJ, **Chawla AJ**, Gavin NI. Preventive services for children under Medicaid, 1989 and 1992. *Health Care Financing Review* 1998; 19(4): 25–44.
- Holzer S**, **Juday TR**, Joellsson B, Crawley JA. Determining the cost of gastroesophageal reflux disease: A decision analytic model. *The American Journal of Managed Care* 1998; 4(10): 1450–1460.
- Hylan T, **Crown W**, **Meneades L**, Heiligenstein J, Melfi C, Croghan T, Buesching D. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: A multivariate analysis. *Journal of Affective Disorders* 1998; 47: 71–79.
- Hylan T, Dossenbach M, **Meneades L**, **Crown W**, Simhandl C. Antidepressant use in the psychiatrist setting in Austria: A comparison of citalopram, fluoxetine, and paroxetine. *Journal of Serotonin Research* 1998; 4: 295–303.
- Hylan TR, **Meneades L**, **Crown WH**, Melfi CA, Croghan TW, Buesching DP. SSRI antidepressant drug use patterns in the naturalistic setting: A multivariate analysis. *European Psychiatry* 1998; 13(Suppl 4): 262s–263s.
- Karner E, **Jackson ME**. Determining comparable levels of functional disability. *AARP Public Policy Issue Brief* 1998; April: 32.
- Krinsky T**. CCHRI 1997—Here we go again. *Journal of the California Health Information Association* 1998; April.
- Krinsky T**. CHIA endorsement paves way for data collection project. *Journal of the California Health Information Association* 1998; Feb.
- Krinsky T**. CPT code revisions for 1998. *Journal of the California Health Information Association* 1998; Feb.
- Larson MJ, Farrelly M, Hodgkin D, **Miller K**, Lubalin J, Witt E, McQuay L, Simpson J, **Pepitone A**, Manderscheid R, Keme A. Payments and use of services for mental health, alcohol, and other drug abuse disorders: Estimates from medicare, medicaid, and private health plans. SAMHSA/CMHS (Center for Mental Health Services) Mental Health, United States, 124–141, 1998.
- Mark TL**, Evans WN, Schur CL, Guterman S. Hospital-physician arrangements and hospital financial performance. *Medical Care* 1998; 36(1): 67–78.
- Mark TL**. Health care reform projections and the line between fact and fiction. In *Health Policy: Understanding Our Choices from National Reform to Market Forces*. Edited by Marilyn M. Rosenthal and Max Heirich. Boulder, CO.: Westview Press, 1998.



- McKusick D, **Mark TL**, King E, Harwood R, Buck JA, Dilonardo J. Mental health and substance abuse expenditure trends and projections. *Health Affairs* 1998; 17(5): 147–157.
- Melfi C, **Chawla A**, Croghan T, Hanna M, **Kennedy S**, **Sredl K**. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. *Archives of General Psychiatry* 1998; 55: 1128–1132.
- Ozminkowski R**, Hylan T, Melfi C, **Meneades L**, **Crown W**, Croghan T, Robinson R. Economic consequences of selected serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P450 system. *Clinical Therapeutics* 1998; 20(4): 780–796.
- Ozminkowski RJ**, **Goetzel RZ**, **Dunn RL**. SAMHSA/CSAP workplace managed care financial/cost research evaluation guide. Division of Workplace Programs, Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration, August 1998.
- Ozminkowski RJ**, White AJ, Hassol A, Murphy M. Predictors of multiple listing for cadaver kidney transplantation and the effects of a ban on multiple listing in the United States—A summary. Chapter 13 in Touraine JL, Traeger J, Betel H, Dubernard JM, Revillard JP, and Dupuy C (eds.), *Organ Allocation, Proceedings of the 30th International Conference on Transplantation and Clinical Immunology*, Dordrecht, Netherlands: Kluwer Academic Publishers, June 1998.
- Ozminkowski RJ**, White AJ, Hassol A, Murphy M. What if socioeconomic made no difference? Access to a cadaver kidney transplant as an example. *Medical Care* 1998; 36 (9): 1398–1406.
- Rosen AK, **Houchens RL**, **Gibson TB**, **Mayer-Oakes A**. Developing episodes of care for adult asthma patients: A cautionary tale. *American Journal of Medical Quality* 1998; 13: 25–35.
- Treglia M, **Neslusan C**, **Dunn R**. SSRI antidepressant selection and concomitant prescribing of anxiolytics and sedative-hypnotics: Evidence from the United Kingdom. *Journal of Medical Economics* 1998; 1: 219–233.
- Walker LC, **Burwell B**. Access to public resources: Regulating asset transfers for long-term care. In Walker, L.C., E.H. Bradley, and T. Wetle. *Public and Private Responsibilities in Long-Term Care: Finding the Balance*. Baltimore, MD: John Hopkins University Press, 1998.
- White AJ, **Ozminkowski RJ**, Hassol A, Dennis JM, Murphy M. The effects of New York state's ban on multiple listing for cadaver kidney transplantation. *Health Services Research* 1998; 33(2 Pt 1): 205–222.

1997 and before

- Barnes CA**, **Mayer-Oakes SA**. The Medicare Quality Indicator System (MQIS): Methodologies, challenges, and lessons learned in quality indicator development. *The Joint Commission Journal on Quality Improvement* 1997; 23(7): 381–90.
- Barnes CA**. Using coded ambulatory data and HEDIS to measure quality of care. *Journal of the California Health Information Association* 1995; 44(6/7): 3–4.



- Brown SL, Lakin KC, **Burwell BO**. Beneficiary centered care in services to persons with developmental disabilities. *Health Care Financing Review* 1997; 19(2): 23–46.
- Burwell B**, Bachman S, Lakin KC. Medicaid community-supported living arrangements. Prouty RW, Lakin KC, eds. In *Residential Services for Persons with Developmental Disabilities: Status and Trends through 1994*. Minneapolis, MN: University of Minnesota, 1995.
- Burwell B, Crown W**, O'Shaugnessy C, Price R. Financing long-term care. In *The Continuum of Long-Term Care: An Integrated Systems Approach*. DelMar Press, 1995. 193–221.
- Burwell B, Crown W**. Medicaid eligibility policy and asset transfers: Does any of this make sense? *Generations* 1996; 20(3): 78–83.
- Burwell B, Crown W**. Medicaid estate planning: Case studies of four states. In *Persons with Disabilities*, Wiener J, Clauser S, Kennel D (eds.). Washington, D.C.: The Brookings Institution.
- Burwell B**. Medicaid estate planning: News from the front lines. In Kane R, Starr L, Baker M, eds. *Who Owes Whom What? Personal, Family and Public Responsibility for Paying for Long-Term Care*. Minneapolis, MN: University of Minnesota School of Public Health, January 1995.
- Coffey R**, Ball J, Johantgen M, Elixhauser A, Purcell P, Andrews R. The case for national health data standards. *Health Affairs* 1997; 16(5): 58–72.
- Coulson N, Terza J, **Neslusan C**, Stuart B. Estimating the moral hazard effect of supplemental medical insurance in the demand for prescription drugs by the elderly. *American Economic Review, Papers and Proceedings* 1995; 85(2): 122–126.
- Croghan, T, **Lair T**, Engelhart L, **Crown W**, Copley-Merriman C, Melfi C, Obenchain R, Buesching D. Effect of antidepressant therapy on health care utilization and costs in primary care. *Psychiatric Services* 1997; 48(11): 1420–1426.
- Crown W**, Chen YP, McConaghy R. The growing interest in older worker employment policy. In Crown (ed.) *Handbook on Employment and the Elderly*. Greenwood Press, 1996; 1–14.
- Crown W**, MacAdam M, Ahlburg D. The demographic and employment characteristics of home care aides: A comparison with nursing home aides, hospital aides and other workers. *The Gerontologist* 1995; 35(2): 162–170.
- Crown W**, Wheat L. State per-capita income convergence since 1950: Causes and their importance. *Journal of Regional Science* 1996.
- Crown W**. Effects of government policies on the incomes of younger and older households. *Encyclopedia on Aging*, 2nd Ed. New York: Springer Publishing Company, 1995.
- Crown W**. Effects of government policies on the incomes of younger and older households. *Encyclopedia on Aging*, 3rd Ed. New York: Springer Publishing Company, 2001.
- Crown W**. *Handbook on Employment and the Elderly*. Greenwood Press, 1996.
- Crown W**. National profile of hospital, nursing home and home health aides. *Generations* 1994; 18(3): 29–33.
- Crown W**. Policy implications of elderly income and wealth taxation. *Generations* 1996; 20(3): 42–45.



- Crown W.** The economic status of the elderly. In L. Vitt and J. Siegenthaler (eds.) *Encyclopedia of Financial Gerontology*. Greenwood Press, 1996; 156–160.
- Crown W.** The political context of older worker employment policy. In Crown (ed.) *Handbook on Employment and the Elderly*. Greenwood Press, 1996; 391–404.
- Cuffel B**, Alford J, Fischer EP, et al. Awareness of illness in schizophrenia and outpatient treatment adherence. *Journal of Nervous and Mental Disease* 1996; 184(11): 653–659.
- Dansky K, Dellasega C, Shellenbarger T, **Russo P.** After hospitalization: Home health care for elderly persons. *Clinical Nursing Research* 1996; 5(2): 185–198.
- Doty P, Stone R, **Jackson ME**, Adler M. Informal caregiving. In C.J. Evashwick, *The Continuum of Long-Term Care: An Integrated Systems Approach*. Delmor Publishers, 1996; 125–141.
- Experton B, Li Z, Branch LG, **Ozminkowski RJ**, Mellon-Lacey D. The impact of payor/provider type on health care utilization and expenditures among the frail elderly. *American Journal of Public Health* 1997; 87: 210–216.
- Experton B, **Ozminkowski RJ**, Branch LG, Li Z. A comparison by payor/provider type of the cost of dying among frail older adults. *Journal of the American Geriatrics Society* 1996; 44: 1098–1107.
- Ghiselli PC, **Barnes CA**, et al. Accuracy of diagnostic coding and its impact on the DRG and disease staging classification systems: A data quality study in the 5 Aziende Ospedaliere of Region Emilia-Romagna (Italy). *Patient Classification System/Europe (PCS/E) 13th International Working Conference Proceeding Book, 1–3 October 1997*. Florence (Italy): 269–74.
- Goetzel RZ**, Kahr TY, Aldana SG, Kenny GM. An evaluation of Duke University's Live for Life health promotion program and its impact on employee health. *American Journal of Health Promotion* 1996; 10(5): 340–2.
- Goetzel RZ.** Essential building blocks for successful worksite health promotion programs. *Managing Employee Health Benefits* 1997; 6(1).
- Heaney CA, **Goetzel RZ.** A review of health-related outcomes of multi-component worksite health promotion programs. *American Journal of Health Promotion* 1997; 11(3): 290–307.
- Heithoff K, **Cuffel B**, **Kennedy S**, **Peters J.** The association between body mass and health care expenditures. *Journal of Clinical Therapeutics* 1997; 19(4): 811–820.
- Holzer S**, Engelhart L, **Crown W**, **L'Herrou T**, **Kennedy S.** Asthma treatment costs using inhaled corticosteroids. *The American Journal of Managed Care* 1997; 3(6): 733–739.
- Hylan T, **Neslusan C**, Baldrige M, **Meneades L**, **Crown W.** SSRI antidepressant selection and anxiolytic and sedative-hypnotic use. *Journal of Clinical Outcomes Management* 1997; 4(4): 16–22.
- Jackson ME**, Doty P. Use of the 1989 National Long-Term Care Survey for examining cognitive impairment eligibility criteria. *Proceeding of the 25th Public Health Conference on Records and Statistics: Data Needs in an Era of Health Reform*, 1994, U.S. Dept. of Health and Human Services: 187–189.
- Jackson ME**, Spector WD, Rabins P. Risk of behavioral problems among nursing home residents in the United States. *Journal of Aging and Health* 1997; 9: 451–472.



- Jacobson BH, Aldana SG, **Goetzel RZ**, Vardell KD, Adams TB, Pietras RJ. The relationship between perceived stress and self-reported illness-related absenteeism. *American Journal of Health Promotion* 1996; 11(1): 54–61.
- Juday T**. Cost-effectiveness analysis: Problems and promise for evaluating medical technology. In *Health Care Technology Policy I: The Role of Technology in the Cost of Health Care*, Warren S. Grundfest, Editor, Proc. SPIE 2307, 1994. 462–467.
- Krinsky T**. CPT code revisions for 1997. *Journal of the California Health Information Association* (Jan. 1997).
- Mark TL**, Mueller CM. Access to care in HMOs and traditional health insurance plans. *Health Affairs* Winter 1996; 15(4): 81–87.
- Mark TL**, Paramore LC. Pneumococcal and influenza vaccination: Access to and use by Hispanic Medicare beneficiaries. *American Journal of Public Health* 1996; 86(11): 1545–1550.
- Mark TL**. Psychiatric hospital ownership and performance. Do nonprofit organizations offer advantages in markets characterized by asymmetric information? *Journal of Human Resources* 1996; 31(3): 631–649.
- Markson LE, Turner BJ, Cocroft J, **Houchens R**, Fanning T. Clinic services for persons with AIDS: Experience in a high prevalence state. *Journal of General Internal Medicine* 1997; 12: 141–149.
- Mauskoph J, Turner BJ, Markson LE, McKee LJ, **Houchens R**, Fanning TR. Patterns of ambulatory care for AIDS patients, and association with emergency room use. *Health Services Research* 1994; 29: 489–510.
- Mayer-Oakes SA**, Atchison KA, Matthias RE, De Jong FJ, Lubben J, Schweitzer SO. Mammography use in older women with regular physicians: What are the predictors? *American Journal of Preventive Medicine* 1996; 12(1): 44–50.
- Merrick N**, Davidson B, Fox S. Treatment of acute gastroenteritis: Too much and too little care. *Clinical Pediatrics* 1996; 35(9): 429–435.
- Neumann P, **Juday T**. Medical technology and rising health expenditures: A review of the estimates. *Health Care Technology Institute* Pub. No. PB94-08, April 1994.
- Ozminkowski RJ**, Aizer A, Smith G. The value and use of the Qualified Medicare Beneficiary Program: Early evidence from Tennessee. *Health and Social Work* 1997; 22(1): 12–19.
- Ozminkowski RJ**, Branch LG. On the economic analysis of interventions for aged populations. In Hickey T and Speers MA (eds.), *Public Health and Aging*, Baltimore, MD: The Johns Hopkins University Press, 1997.
- Ozminkowski RJ**, Branch LG. Predictors of home care use. In Romaine-Davis A, et al., (eds.), *Encyclopedia of Home Care for the Elderly*, Westport, CT: Greenwood Press, 1995.
- Ozminkowski RJ**, Hassol A, Firkusny I, Noether M, Miles MA, Newmann J, Sharda C, Guterman S, Schmitz R. Estimating increases in outpatient dialysis costs resulting from scientific and technological advancement. *Advances in Renal Replacement Therapy* 1995; 2(2): 127–142.



- Ozminkowski RJ**, Hassol A, White AJ, Murphy M, Dennis JM, Shield CF. Socioeconomic factors and multiple listing for cadaveric kidney transplantation among Medicare end-stage renal disease program beneficiaries. *Transplantation Reviews* 1997; 11(2): 70–75.
- Ozminkowski RJ**, Noether M, Nathanson P, Smith KM, Raney BE, Mickey M, Hawley PM. Profiling primary care physicians for a new managed care network. *Health Services Management Research* 1997; 10: 173–186.
- Ozminkowski RJ**, White AJ, Hassol A, Murphy M. General health of end-stage renal disease program beneficiaries. *Health Care Financing Review* 1997; 19(1): 121–144.
- Ozminkowski RJ**, White AJ, Hassol A, Murphy M. Minimizing racial disparity regarding receipt of a cadaver kidney transplant. *American Journal of Kidney Diseases* 1997; 30(6): 749–759.
- Pearlman DN, Branch LG, **Ozminkowski RJ**, Experton B, Li Z. Transitions in health care use and expenditures among frail older adults by payor/provider type. *Journal of the American Geriatrics Society* 1997; 45: 550–557.
- Spector WD, **Jackson ME**. Correlates of disruptive behavior: A re-analysis. *Journal of Aging and Health* 1994; 6: 173–184.
- Turner BJ, Markson LE, **Houchens R**, Fanning T. Research on outcomes using a Medicaid AIDS database: Overcoming the curses of imperfect data. *Medical Effectiveness Research Data Methods*. Ed. M.L. Grady. Agency for Health Care Policy and Research, Rockville, MD (July 1992).
- White AJ, **Ozminkowski RJ**, Hassol A, Dennis JM, Murphy M. The relationship between multiple listing and cadaveric kidney transplantation and the effects of a multiple listing ban. *Transplantation Reviews* 1997; 11(2): 76–83.

To contact Thomson Reuters regarding these and other authored studies, please call +1 866 301 5419 or e-mail medstat.marketscan@thomson.com.

(422)